Kamada (KMDA) said Wednesday it opened a new plasma collection center in San Antonio, Texas, with an expected annual collection capacity of about 50,000 liters.
The plasma-derived protein therapeutics manufacturer said the new facility will collect normal source plasma for third-party sales and specialty plasma, including Anti-Rabies and Anti-D, for internal use.
The company said it expects sales of normal source plasma from the site to generate $8 million to $10 million annually at full capacity.
Kamada said it plans to seek regulatory approvals for the new site from the US Food and Drug Administration and the European Medicines Agency in H2.
Price: 6.69, Change: +0.03, Percent Change: +0.45
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。